<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935841</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-56-19</org_study_id>
    <nct_id>NCT03935841</nct_id>
  </id_info>
  <brief_title>Metabolic Differences of an Oral and Intravenous Dose of 3-hydroxybutyrate (3-OHB).</brief_title>
  <official_title>Metabolic Differences of an Oral and Intravenous Dose of 3-hydroxybutyrate (3-OHB).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-labeled intervention study testing healthy, lean, and male volunteers on two separate
      occasions:

        1. blood sampling after consuming 36 gram 3-Hydroxybutyrate (3-OHB) salt.

        2. blood sampling while given a variable rate of 3-OHB salt intravenously to replicate the
           concentrations seen during oral consumption.

      The primary outcome is differences in insulin concentrations (incremental AUC) 180 minutes
      after 3-OHB consumed orally vs. intravenously.

      Secondary outcomes includes iAUC for other gastrointestinal hormones and substrates
      (Glucagon, GLP-1, GIP, glucose, and 3-OHB) Gastric emptying will be evaluated using 1500 mg
      Paracetamol consumption before each intervention day. Urine will be analyzed for ketone
      concentrations/excretion rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-labeled intervention study testing healthy, lean, and male volunteers on two separate
      occasions with at least 48 hours apart.

        1. blood sampling after consuming 36 gram 3-Hydroxybutyrate (3-OHB) salt.

        2. blood sampling while given a variable rate of 3-OHB salt intravenously to replicate the
           concentrations seen during oral consumption.

      The primary outcome is differences in insulin concentrations (incremental AUC) 180 minutes
      after 3-OHB consumed orally vs. intravenously.

      Secondary outcomes includes iAUC for other gastrointestinal hormones and substrates
      (Glucagon, GLP-1, GIP, glucose, and 3-OHB) Gastric emptying will be evaluated using 1500 mg
      Paracetamol consumption before each intervention day. Urine will be analyzed for ketone
      concentrations/excretion rates.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 7, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma insulin</measure>
    <time_frame>180 minutes</time_frame>
    <description>incremental area under the curve (iAUC) for plasma insulin concentrations {pmol/l}</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucagon</measure>
    <time_frame>180 minutes</time_frame>
    <description>iAUC and concentrations of (Glucagon {pg/ml}</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying</measure>
    <time_frame>180 minutes</time_frame>
    <description>Paracetamol test, 1500 mg following interventions and measuring plasma paracetamol {micromol/l}</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine 3-OHB</measure>
    <time_frame>180 minutes</time_frame>
    <description>Excretion rates {gram/hour} will be estimated as = urine output {L} x urine 3-OHB concentration {mmol/l} x 0.1041 {g/mmol}/180 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma GLP1</measure>
    <time_frame>180 minutes</time_frame>
    <description>iAUC and concentrations of GLP-1 {pmol/l},</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma GIP</measure>
    <time_frame>180 minutes</time_frame>
    <description>iAUC and concentrations of GIP {pmol/l},</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>180 minutes</time_frame>
    <description>iAUC and concentrations of glucose {mmol/l},</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma free fatty acids</measure>
    <time_frame>180 minutes</time_frame>
    <description>iAUC and concentrations of free fatty acids {mmol/l},</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 3-OHB</measure>
    <time_frame>180 minutes</time_frame>
    <description>iAUC and concentrations of 3-OHB {mmol/l})</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Ghrelin</measure>
    <time_frame>180 minutes</time_frame>
    <description>iAUC and concentrations of Ghrelin {ng/l})</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PYY</measure>
    <time_frame>180 minutes</time_frame>
    <description>iAUC and concentrations of PYY {pg/ml})</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>height</measure>
    <time_frame>at time 0 minutes</time_frame>
    <description>height {meters}</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>at time 0 minutes</time_frame>
    <description>weight {kg}</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>time 0 minutes</time_frame>
    <description>Body mass index = weight/height^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>time 0 minutes and 180 minutes</time_frame>
    <description>Arm blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety questionnaire (Blundell et al. 2010)</measure>
    <time_frame>At 0, 60, 120, and 180 minutes</time_frame>
    <description>VAS/NRS-score of hunger, fullness, satiety, desire, and prospective consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ad libitum food intake</measure>
    <time_frame>at time = 180 minutes</time_frame>
    <description>gram (and kcal) intake of an ad libitum meal (sandwich)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <condition>Incretin Effect</condition>
  <condition>Ketosis</condition>
  <arm_group>
    <arm_group_label>3-OHB orally</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>36 gram 3-OHB salt consumed orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-OHB intravenously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Variable amounts of 3-OHB salt given i order to replicate the same individual plasma concentrations measured during the experimental arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>3-OHB salt (NaCl)</intervention_name>
    <description>36 gram 3-OHB salt diluted in 500 ml sterile water</description>
    <arm_group_label>3-OHB intravenously</arm_group_label>
    <arm_group_label>3-OHB orally</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  19&lt;BMI&lt;30

          -  written og oral consent

          -  No allergies to paracetamol

        Exclusion Criteria:

          -  Chronic disease or daily medical treatment

          -  Daily intake of ketones or ketogenic diets

          -  Speaks and understands Danish

          -  Screening blood sample abnormalities
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Jessen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Steno Diabetes Center Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Diabetes and Hormone Diseases (DoH)</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Nikolaj Fibiger Rittig</investigator_full_name>
    <investigator_title>Principal investigator, MD, PhD, and clinical researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

